Lv1
56 积分 2024-09-12 加入
INCIDENCE AND RISK FACTORS OF INTRAOCULAR INFLAMMATION AFTER BROLUCIZUMAB TREATMENT IN JAPAN
7小时前
已完结
Conversion to faricimab after prior anti-vascular endothelial growth factor therapy for persistent diabetic macular oedema
1个月前
已完结
A case of hypertensive uveitis with intravitreal faricimab
2个月前
已关闭
Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial
2个月前
已完结
Comparison between intravitreal brolucizumab and aflibercept in the treatment-naive central involved diabetic macular edema: One-year real-life case series
2个月前
已完结
Pro Re Nata brolucizumab for early onset and treatment-naïve diabetic macular edema: A prospective study
2个月前
已完结
Intraocular drugs: pharmacokinetic strategies and the influence on efficacy and durability
2个月前
已完结
Outcomes of Diabetic Macular Edema Eyes with Limited Early Response in the VISTA and VIVID Studies
3个月前
已关闭
Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial
4个月前
已完结
Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial
4个月前
已完结
皖公网安备34019202002308
